Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/40382
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPugliatti, M-
dc.contributor.authorHartung, HP-
dc.contributor.authorOreja-Guevara, C-
dc.contributor.authorPozzilli, C-
dc.contributor.authorAiras, L-
dc.contributor.authorAlkhawajah, M-
dc.contributor.authorGrigoriadis, N-
dc.contributor.authorMagyari, M-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorZakaria, M-
dc.contributor.authorLinker, R-
dc.contributor.authorChan, A-
dc.contributor.authorVermersch, P-
dc.contributor.authorBerger, T-
dc.date.accessioned2023-06-13T15:31:05Z-
dc.date.available2023-06-13T15:31:05Z-
dc.date.issued2022-
dc.date.submitted2023-06-06T09:06:37Z-
dc.identifier.citationFrontiers in Immunology, 13 (Art N° 1045101)-
dc.identifier.issn1664-3224-
dc.identifier.urihttp://hdl.handle.net/1942/40382-
dc.description.abstractIt has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.-
dc.description.sponsorshipFunding The authors acknowledge the financial and operational support of the ParadigMS Foundation that made it possible to produce this article. ParadigMS activities are co-funded by Sanofi, Roche and Merck. Acknowledgments We would like to thank Monica Hoyos of Springer Healthcare Communicationsformedicalwriting assistancefunded byParadigMS Foundation. ParadigMS Foundation is a group of European, Middle Eastern andNorthAfrican expertsinmultiple sclerosis.The content of this publicationis based uponin-depth discussions on this topic by the groupmembersatExpertMeetings.Thecurrentlist ofgroupmembers can be consulted at ParadigMS’s website.-
dc.language.isoen-
dc.publisherFRONTIERS MEDIA SA-
dc.rights2022 Pugliatti, Hartung, Oreja-Guevara, Pozzilli, Airas, Alkhawajah, Grigoriadis, Magyari, Van Wijmeersch, Zakaria, Linker, Chan, Vermersch and Berger. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.-
dc.subject.otherCOVID-19-
dc.subject.othervaccines-
dc.subject.otherSARS-CoV-2-
dc.subject.othermultiple sclerosis-
dc.subject.otherdisease modifying therapies-
dc.subject.otherimmune response-
dc.subject.otheradverse events-
dc.titleAnti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in-
dc.typeJournal Contribution-
dc.identifier.volume13-
local.format.pages8-
local.bibliographicCitation.jcatA1-
local.publisher.placeAVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND-
local.type.refereedRefereed-
local.type.specifiedReview-
local.bibliographicCitation.artnr1045101-
dc.identifier.doi10.3389/fimmu.2022.1045101-
dc.identifier.pmid36325318-
dc.identifier.isi000891688600001-
dc.identifier.eissn1664-3224-
local.provider.typeWeb of Science-
local.uhasselt.internationalyes-
item.fulltextWith Fulltext-
item.contributorPugliatti, M-
item.contributorHartung, HP-
item.contributorOreja-Guevara, C-
item.contributorPozzilli, C-
item.contributorAiras, L-
item.contributorAlkhawajah, M-
item.contributorGrigoriadis, N-
item.contributorMagyari, M-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorZakaria, M-
item.contributorLinker, R-
item.contributorChan, A-
item.contributorVermersch, P-
item.contributorBerger, T-
item.fullcitationPugliatti, M; Hartung, HP; Oreja-Guevara, C; Pozzilli, C; Airas, L; Alkhawajah, M; Grigoriadis, N; Magyari, M; VAN WIJMEERSCH, Bart; Zakaria, M; Linker, R; Chan, A; Vermersch, P & Berger, T (2022) Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in. In: Frontiers in Immunology, 13 (Art N° 1045101).-
item.accessRightsOpen Access-
item.validationecoom 2023-
crisitem.journal.issn1664-3224-
crisitem.journal.eissn1664-3224-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
fimmu-13-1045101.pdfPublished version635.75 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.